Ribon Therapeutics' Series B Round

Ribon Therapeutics raised a round of funding on October 10, 2017.

Ribon Therapeutics is pioneering the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells' fundamental ability to survive under stress.…

Articles about Ribon Therapeutics' Series B Round: